Compare AGNC Investment Corp (AGNC) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGNC Investment Corp vs Merck & Co., Inc. — how do they compare? AGNC Investment Corp trades at $10.91 (market cap $12.91B), while Merck & Co., Inc. trades at $132.93 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 24.9× AGNC Investment Corp's market cap, and AGNC Investment Corp pays the higher dividend (13.22%). Which is the better fit depends on your goals.
| AGNC | MRK | |
|---|---|---|
Market Cap | $12.91B | $321.77B |
Sector | Financials | Health |
52-Week High | $12.17 | $131.84 |
52-Week Low | $9.46 | $77.60 |
Dividend Yield | 13.22% | 2.61% |
Enterprise Value | — | $368.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGNC Investment trades at $10.925, up 1.53% today, with a bullish technical signal from moving averages. The mortgage REIT shows strong profitability with a 94.38% net income margin and 21.67% ROE, though it missed Q4 2025 EPS estimates. Recent analyst upgrades and consistent monthly dividends highlight income appeal, while the stock trades modestly above its $8.58 book value. Cash flow trends indicate active portfolio management with significant investing and financing activities.
Outlook: AGNC offers high yield income potential with a secure dividend history, but faces interest rate sensitivity and valuation constraints. Risks include mortgage spread volatility and leveraged portfolio exposure. Analyst consensus is mixed with a $11.30 price target suggesting limited upside from current levels.
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, supported by analyst consensus favoring a buy rating (67.57%) and a price target of $140.36. Key opportunities include pipeline expansion through M&A and solid cash flow generation. Risks involve high valuation multiples, such as a P/E of 104.34, and potential integration challenges from acquisitions. Investors should weigh growth prospects against elevated earnings expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
